Application of prothrombin complex concentrate for reversal of direct oral anticoagulants in clinical practice: indications, patient characteristics and clinical outcomes compared to reversal of vitamin K antagonists
Abstract Background Prothrombin complex concentrate (PCC) is widely used to reverse the action of direct oral anticoagulants (DOACs) in accordance with current guidelines and because of a lack of specific reversal agents. Indications, clinical characteristics and patient outcomes of patients might d...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2019-04-01
|
| Series: | Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s13049-019-0625-3 |
| _version_ | 1811223900049113088 |
|---|---|
| author | Martin Müller Jonathan Eastline Michael Nagler Aristomenis K. Exadaktylos Thomas C. Sauter |
| author_facet | Martin Müller Jonathan Eastline Michael Nagler Aristomenis K. Exadaktylos Thomas C. Sauter |
| author_sort | Martin Müller |
| collection | DOAJ |
| description | Abstract Background Prothrombin complex concentrate (PCC) is widely used to reverse the action of direct oral anticoagulants (DOACs) in accordance with current guidelines and because of a lack of specific reversal agents. Indications, clinical characteristics and patient outcomes of patients might differ in comparison to reversal of vitamin K antagonists where reversal with PCC is well established. Methods Our cohort study explores patient characteristics, indications and clinical outcomes for reversal of all DOAC patients receiving PCC at our university emergency department from 01.06.2012 to 01.07.2017, in comparison with patients on VKA. Results Out of 199,982 consultations, we studied 346 patients who were given PCC for reversal of either DOAC (n = 74) or VKA (n = 272). The most common reason for treatment was acute bleeding; in 86.7% of both groups. 37.3% of bleeding was traumatic (p = 0.666). The most frequent bleeding location was intracranial (61.6%, p = 0.881). Gastrointestinal bleeding was more often found in the DOAC group (18.9% vs. 8.8%, p = 0.014). More erythrocyte concentrates (ECs) were given to DOAC patients with blood transfusion (p = 0.014). Tranexamic acid was used more often in DOAC patients than in VKA patients (28.4% vs. 7.4%, p < 0.001). No significant group differences were found for the following patient outcomes: in-hospital mortality, ICU stay, and length of stay at the ICU or in hospital. Conclusion In DOAC treated patients, PCC was applied more often because of gastrointestinal bleeding and patients received higher numbers of ECs as well as tranexamic acid. No differences were observed with regard to important clinical outcomes. |
| first_indexed | 2024-04-12T08:41:27Z |
| format | Article |
| id | doaj.art-2d43b0c3faa546c1814ba61947447c79 |
| institution | Directory Open Access Journal |
| issn | 1757-7241 |
| language | English |
| last_indexed | 2024-04-12T08:41:27Z |
| publishDate | 2019-04-01 |
| publisher | BMC |
| record_format | Article |
| series | Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine |
| spelling | doaj.art-2d43b0c3faa546c1814ba61947447c792022-12-22T03:39:52ZengBMCScandinavian Journal of Trauma, Resuscitation and Emergency Medicine1757-72412019-04-012711910.1186/s13049-019-0625-3Application of prothrombin complex concentrate for reversal of direct oral anticoagulants in clinical practice: indications, patient characteristics and clinical outcomes compared to reversal of vitamin K antagonistsMartin Müller0Jonathan Eastline1Michael Nagler2Aristomenis K. Exadaktylos3Thomas C. Sauter4Department of Emergency Medicine, Inselspital, Bern University Hospital, Bern UniversityDepartment of Emergency Medicine, Inselspital, Bern University Hospital, Bern UniversityUniversity Institute of Clinical Chemistry, Inselspital Bern University Hospital, and University of BernDepartment of Emergency Medicine, Inselspital, Bern University Hospital, Bern UniversityDepartment of Emergency Medicine, Inselspital, Bern University Hospital, Bern UniversityAbstract Background Prothrombin complex concentrate (PCC) is widely used to reverse the action of direct oral anticoagulants (DOACs) in accordance with current guidelines and because of a lack of specific reversal agents. Indications, clinical characteristics and patient outcomes of patients might differ in comparison to reversal of vitamin K antagonists where reversal with PCC is well established. Methods Our cohort study explores patient characteristics, indications and clinical outcomes for reversal of all DOAC patients receiving PCC at our university emergency department from 01.06.2012 to 01.07.2017, in comparison with patients on VKA. Results Out of 199,982 consultations, we studied 346 patients who were given PCC for reversal of either DOAC (n = 74) or VKA (n = 272). The most common reason for treatment was acute bleeding; in 86.7% of both groups. 37.3% of bleeding was traumatic (p = 0.666). The most frequent bleeding location was intracranial (61.6%, p = 0.881). Gastrointestinal bleeding was more often found in the DOAC group (18.9% vs. 8.8%, p = 0.014). More erythrocyte concentrates (ECs) were given to DOAC patients with blood transfusion (p = 0.014). Tranexamic acid was used more often in DOAC patients than in VKA patients (28.4% vs. 7.4%, p < 0.001). No significant group differences were found for the following patient outcomes: in-hospital mortality, ICU stay, and length of stay at the ICU or in hospital. Conclusion In DOAC treated patients, PCC was applied more often because of gastrointestinal bleeding and patients received higher numbers of ECs as well as tranexamic acid. No differences were observed with regard to important clinical outcomes.http://link.springer.com/article/10.1186/s13049-019-0625-3AnticoagulantsAntidoteBleedingDirect oral anticoagulantsVitamin K antagonist |
| spellingShingle | Martin Müller Jonathan Eastline Michael Nagler Aristomenis K. Exadaktylos Thomas C. Sauter Application of prothrombin complex concentrate for reversal of direct oral anticoagulants in clinical practice: indications, patient characteristics and clinical outcomes compared to reversal of vitamin K antagonists Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine Anticoagulants Antidote Bleeding Direct oral anticoagulants Vitamin K antagonist |
| title | Application of prothrombin complex concentrate for reversal of direct oral anticoagulants in clinical practice: indications, patient characteristics and clinical outcomes compared to reversal of vitamin K antagonists |
| title_full | Application of prothrombin complex concentrate for reversal of direct oral anticoagulants in clinical practice: indications, patient characteristics and clinical outcomes compared to reversal of vitamin K antagonists |
| title_fullStr | Application of prothrombin complex concentrate for reversal of direct oral anticoagulants in clinical practice: indications, patient characteristics and clinical outcomes compared to reversal of vitamin K antagonists |
| title_full_unstemmed | Application of prothrombin complex concentrate for reversal of direct oral anticoagulants in clinical practice: indications, patient characteristics and clinical outcomes compared to reversal of vitamin K antagonists |
| title_short | Application of prothrombin complex concentrate for reversal of direct oral anticoagulants in clinical practice: indications, patient characteristics and clinical outcomes compared to reversal of vitamin K antagonists |
| title_sort | application of prothrombin complex concentrate for reversal of direct oral anticoagulants in clinical practice indications patient characteristics and clinical outcomes compared to reversal of vitamin k antagonists |
| topic | Anticoagulants Antidote Bleeding Direct oral anticoagulants Vitamin K antagonist |
| url | http://link.springer.com/article/10.1186/s13049-019-0625-3 |
| work_keys_str_mv | AT martinmuller applicationofprothrombincomplexconcentrateforreversalofdirectoralanticoagulantsinclinicalpracticeindicationspatientcharacteristicsandclinicaloutcomescomparedtoreversalofvitaminkantagonists AT jonathaneastline applicationofprothrombincomplexconcentrateforreversalofdirectoralanticoagulantsinclinicalpracticeindicationspatientcharacteristicsandclinicaloutcomescomparedtoreversalofvitaminkantagonists AT michaelnagler applicationofprothrombincomplexconcentrateforreversalofdirectoralanticoagulantsinclinicalpracticeindicationspatientcharacteristicsandclinicaloutcomescomparedtoreversalofvitaminkantagonists AT aristomeniskexadaktylos applicationofprothrombincomplexconcentrateforreversalofdirectoralanticoagulantsinclinicalpracticeindicationspatientcharacteristicsandclinicaloutcomescomparedtoreversalofvitaminkantagonists AT thomascsauter applicationofprothrombincomplexconcentrateforreversalofdirectoralanticoagulantsinclinicalpracticeindicationspatientcharacteristicsandclinicaloutcomescomparedtoreversalofvitaminkantagonists |